While Epogen and Neupogen addresses anemia and neutropenia, no therapy has existed for the treatment of lymphopenia until ANKTIVA® –The Cancer BioShield. Landmark overall survival benefit (P-value ...
In the global intention-to-treat population, Pola-R-CHP showed significant progression-free survival benefit over R-CHOP ...
ImmunityBio, Inc.’s Anktiva shows promise for bladder cancer, but faces FDA setbacks and a rocky approval path. Peak sales for Anktiva’s indications could reach $900 million by 2028, implying a 73% ...
To confirm a diagnosis and determine the stage of the disease, your doctor will use a series of tests: Biopsy: This is the most definitive test. A surgeon will remove all or part of an affected lymph ...
Over the past decade, there has been a significant increase in the number of approved drugs for treating lymphoma. Before the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback